Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide α

Journal of Natural Products

Volumn 68, Issue 4, 2005, Pages 550-553

  Connolly, Timothy P ^a   Regueiro Ren, Alicia ^a   Leet, John E ^a   Springer, Dane M ^a   Goodrich, Jason ^a   Huang, Xiaohua ^a   Pucci, Michael J ^a   Clark, Junius M ^a   Bronson, Joanne J ^a   Ueda, Yasutsugu ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOTHIOHEXIDE ALPHA; INDOLE DERIVATIVE; LACTONE DERIVATIVE; NOCATHIACIN 1; NOCATHIACIN 2; NOCATHIACIN 4; NOCATHIACIN 5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; CHEMICAL PROCEDURES; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; HYDROLYSIS; IN VIVO STUDY; INFECTION; MOUSE; NONHUMAN;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; MICE; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PEPTIDES; PEPTIDES, CYCLIC; THIAZOLES;

EID: 20244387138     PISSN: 01633864     EISSN: None     Source Type: Journal    
DOI: 10.1021/np040225d     Document Type: Article

References (30)

1. For recent reviews on antibacterial resistance: see (a) Sefton, A. M. Drugs 2002, 62, 557-566. (b) Tenover, T. C. Clin. Infect. Dis. 2001, 33 (Suppl. 3), S108-115. (c) Barbosa, T. M.; Levy, S. B. Drug Resist. Updates 2000, 3, 303-311.
2. For recent reviews on antibacterial resistance: see (a) Sefton, A. M. Drugs 2002, 62, 557-566. (b) Tenover, T. C. Clin. Infect. Dis. 2001, 33 (Suppl. 3), S108-115. (c) Barbosa, T. M.; Levy, S. B. Drug Resist. Updates 2000, 3, 303-311.
3. For recent reviews on antibacterial resistance: see (a) Sefton, A. M. Drugs 2002, 62, 557-566. (b) Tenover, T. C. Clin. Infect. Dis. 2001, 33 (Suppl. 3), S108-115. (c) Barbosa, T. M.; Levy, S. B. Drug Resist. Updates 2000, 3, 303-311.
4. (a) Bush, K.; Macielag, M.; Clancy, J. Emerging Drugs 2000, 5, 347-365, and references therein.
5. (b) Walsh, C. Nature 2000, 406, 775-781, and references therein.
6. (a) Leet, J. E.; Ax, H. A.; Gustavson, D. R.; Brown, D. M.; Turner, L.; Brown, K.; Li, W.; Lam, K. S. US 6,218,398 (April 17, 2001); Chem Abstr. 2000, 132, 121531.
7. (a) Leet, J. E.; Ax, H. A.; Gustavson, D. R.; Brown, D. M.; Turner, L.; Brown, K.; Li, W.; Lam, K. S. US 6,218,398 (April 17, 2001); Chem Abstr. 2000, 132, 121531.
8. (b) Li, W.; Leet, J. E.; Ax, H. A.; Gustavson, D. R.; Brown, D. M.; Turner, L.; Brown, K.; Clark, J.; Yang, H.; Fung-Tomc, J.; Lam, K. S. J. Antibiot. 2003, 56, 226-231.
9. (c) Leet, J. E.; Li, W.; Ax, H. A.; Matson, J. A.; Lam, K. S.; Huang, S.; Huang, R.; Cantone, J.; Drexler, D.; Dalterio,; R. A.; Lam, K. S. J. Antibiot. 2003, 56, 232-242.
10. (d) For stereochemical assignment of nocathiacin I, see: Constantine, K. L.; Mueller, L.; Huang, S.; Abid, S.; Lam, K. S.; Li, W.; Leet, J. E. J. Am. Chem. Soc. 2002, 124, 7284-7285.
11. (e) Pucci, M. J.; Bronson, J. J.; Barrett, J. F.; DenBleyker, K. L.; Discotto, L. F.; Fung-Tomc, J. C.; Ueda, Y. Antimicrob. Agents Chemother. 2004, 48, 3697-3701.
12. Sasaki, T.; Otani, T.; Matsumoto, H.; Hamada, M.; Takeuchi, T.; Hori, M. J. Antibiot. 1998, 51, 715-721.
13. (a) Steinberg, D. A.; Bernan, V. S.; Montenegro, D. A.; Abbanat, D. R.; Pearce, C. J.; Korshalla, J. D.; Jacobus, N. V.; Petersen, P. J.; Mroczenski-Wildey, M. J.; Maiese, W. M.; Greenstein, M. J. Antibiot. 1994, 47, 887-893.
14. (b) Northcote, P. T.; Williams, D.; Manning, J. K.; Borders, D. B.; Maiese, W. M.; Lee, M. D. J. Antibiot. 1994, 47, 894-900.
15. (c) Northcote, P. T.; Siegel, M.; Borders, D. B.; Lee, M. D. J. Antibiot. 1994, 47, 901-908.
16. (d) Its stereochemical assignment is not reported.
17. Keller-Juslen, C.; Kuhn, M.; King, H. D. US 4,478,831 (October 23, 1984); Chem. Abstr. 1985, 102, 77266.
18. Keller-Juslen, C.; Kuhn, M.; King, H. D. US 4,478,831 (October 23, 1984); Chem. Abstr. 1985, 102, 77266.
19. (a) Pascard, C.; Ducruix, A.; Lunel, J.; Prange, T. J. Am. Chem. Soc. 1977, 99, 6418-6423.
20. (b) Benazet, F.; Cartier, M.; Florent, J.; Godard, C.; Jung, G.; Lunel, J.; Mancy, D.; Pascal, C.; Renaut, J.; Tarridec, P.; Theilleux, J.; Tissier, R.; Dubost, M,; Ninest, L. Experientia 1980, 36, 414-416.
21. (c) Mocek, U.; Chen, L.-C.; Keller, P. J.; Houck, D. R.; Beale, J. M.; Floss, H. G. J. Antibiot. 1989, 42, 1643-1648.
22. (a) Regueiro-Ren, A.; Ueda, Y. J. Org. Chem. 2002, 67, 8699-8702.
23. (b) Li, W.; Leet, J. E.; Huang, S.; Lam, K. S.; Regueiro-Ren, A. PCT Int. Appl. WO 0213834 (Feb 21, 2002); Chem. Abstr. 2002, 136, 182552.
24. (b) Li, W.; Leet, J. E.; Huang, S.; Lam, K. S.; Regueiro-Ren, A. PCT Int. Appl. WO 0213834 (Feb 21, 2002); Chem. Abstr. 2002, 136, 182552.
25. Hrnciar, P.; Ueda, Y.; Huang, S.; Leet, J. E.; Bronson, J. J. J. Org. Chem. 2002, 67, 8789-8793.
26. We name this lactone analogue of glycothiohexide-α as nocathiacin V.
27. Regueiro-Ren, A.; Naidu, B. N.; Zheng, X.; Hudyma, T. W.; Connolly, T. P.; Matiskella, J. D.; Zhang, Y.; Kim, O. K.; Sorenson, M. E.; Pucci, M.; Clark, J.; Bronson, J. J.; Ueda, Y. Bioorg. Med. Chem. Lett. 2003, 14, 171-175.
28. (a) Somei, M.; Tsuchiya, M. Chem. Pharm. Bull. 1981, 29, 3145-3157.
29. (b) Gorlitzer, K.; Ventzke-Neu, K. Pharmazie 1997, 52, 919-926.
30. 50 is defined as the dose at which 50% of the total number of animals tested are protected from the infection, and survived.